Manish Singh
Plus aucun poste en cours
Profil
Manish Singh was the founder of Aliva Biopharmaceuticals, Inc. founded in 2006, where he held the title of Chief Executive Officer in 2007.
He was also a Director at California Technology Ventures from 2003 to 2007.
Dr. Singh's former jobs include being the President, CEO & Independent Director at ImmunoCellular Therapeutics Ltd.
from 2008 to 2012, Chief Executive Officer at Iovance Biotherapeutics, Inc. in 2014, Principal at Cell Genesys, Inc., Manager at Genetic Therapy, Inc., and Manager at Chiron Viagene, Inc. Dr. Singh's education history includes an MBA from the University of California, Los Angeles, a graduate degree from Worcester Polytechnic Institute, and an undergraduate degree from Indian Institute of Technology Roorkee.
Anciens postes connus de Manish Singh
| Sociétés | Poste | Fin |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Directeur Général | 31/12/2014 |
| EOM PHARMACEUTICALS HOLDINGS, INC. | President | 20/08/2012 |
California Technology Ventures
 California Technology Ventures Investment ManagersFinance California Technology Ventures LLC (California Technology Ventures) is a venture capital subsidiary of Jacobs Capital Group LLC founded in 1999 by Alex B. Suh. The firm is headquartered in Pasadena, California. | Private Equity Investor | 31/12/2007 |
Aliva Biopharmaceuticals, Inc.
 Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | Fondateur | 01/12/2007 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | - |
Formation de Manish Singh
| University of California, Los Angeles | Masters Business Admin |
| Worcester Polytechnic Institute | Graduate Degree |
| Indian Institute of Technology Roorkee | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
California Technology Ventures
California Technology Ventures Investment ManagersFinance California Technology Ventures LLC (California Technology Ventures) is a venture capital subsidiary of Jacobs Capital Group LLC founded in 1999 by Alex B. Suh. The firm is headquartered in Pasadena, California. | Finance |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
Chiron Viagene, Inc.
 Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Commercial Services |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
ImmunoCellular Therapeutics Ltd.
 ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
Aliva Biopharmaceuticals, Inc.
Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | Health Technology |
